盐水耦联双极射频系统在骨肿瘤治疗中的应用及安全评估

注册号:

Registration number:

ChiCTR2500115202 

最近更新日期:

Date of Last Refreshed on:

2025-12-23 17:27:58 

注册时间:

Date of Registration:

2025-12-23 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

盐水耦联双极射频系统在骨肿瘤治疗中的应用及安全评估

Public title:

Application and Safety Evaluation of Saline-Coupled Bipolar Radiofrequency Systems in the Treatment of Bone Tumors

注册题目简写:

English Acronym:

研究课题的正式科学名称:

盐水耦联双极射频系统在骨肿瘤治疗中的应用及安全评估

Scientific title:

Application and Safety Evaluation of Saline-Coupled Bipolar Radiofrequency Systems in the Treatment of Bone Tumors

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

金青林 

研究负责人:

李浩淼 

Applicant:

Qinglin Jin 

Study leader:

Haomiao Li 

申请注册联系人电话:

Applicant telephone:

+86 15626453765

研究负责人电话:

Study leader's
telephone:

+86 20 62784553

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15626453765@163.com

研究负责人电子邮件:

Study leader's E-mail:

lihaomiao1977@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市天河区中山大道西183号

研究负责人通讯地址:

广州市天河区中山大道西183号

Applicant address:

No. 183, Zhongshan Avenue West, Tianhe District, Guangzhou

Study leader's address:

No. 183, Zhongshan Avenue West, Tianhe District, Guangzhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学第三附属医院

Applicant's institution:

The Third Affiliated Hospital of Southern Medical University

研究负责人所在单位:

南方医科大学第三附属医院(广东省骨科研究院)

Affiliation of the Leader:

The Third Affiliated Hospital of Southern Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-ER-068

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南方医科大学第三附属医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of the Third Affiliated Hospital of Southern Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-26 00:00:00

伦理委员会联系人:

李俊彦

Contact Name of the ethic committee:

Li Junyan

伦理委员会联系地址:

广州市天河区中山大道西183号

Contact Address of the ethic committee:

No. 183, Zhongshan Avenue West, Tianhe District, Guangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 62784067

伦理委员会联系人邮箱:

Contact email of the ethic committee:

441278792@qq.com

研究实施负责(组长)单位:

南方医科大学第三附属医院(广东省骨科研究院)

Primary sponsor:

The Third Affiliated Hospital of Southern Medical University

研究实施负责(组长)单位地址:

广州市天河区中山大道西183号

Primary sponsor's address:

No. 183, Zhongshan Avenue West, Tianhe District, Guangzhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

南方医科大学第三附属医院(广东省骨科研究院)

具体地址:

广州市天河区中山大道西183号

Institution
hospital:

The Third Affiliated Hospital of Southern Medical University

Address:

No. 183, Zhongshan Avenue West, Tianhe District, Guangzhou

经费或物资来源:

广州市临床高新、重大和特色技术项目

Source(s) of funding:

Guangzhou Municipal Clinical High-Tech, Major, and Distinctive Technology Projects

研究疾病:

良性骨肿瘤(内生软骨瘤;软骨母细胞瘤;骨样骨瘤;骨瘤;动脉瘤样骨囊肿;非骨化性纤维瘤;骨的纤维结构不良)及中间型(非典型软骨肿瘤 ;骨母细胞瘤;骨巨细胞瘤)  

Target disease:

Benign Bone Tumors(Enchondroma;Chondroblastoma;Osteoid osteoma;Osteoma;Aneurysmal bone cyst ;Non-ossifying fibroma ;Fibrous dysplasia of bone) Intermediate Bone Tumors(Atypical cartilaginous tumor; Osteoblastoma; Giant cell tumor of bone)

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

主要目的 :探讨盐水耦联双极射频系统在良性或中间型骨肿瘤患者的手术中的辅助灭活能力 次要目的:探讨盐水耦联双极射频系统在良性或中间型骨肿瘤患者的术中应用的安全性  

Objectives of Study:

Primary Objective: To evaluate the adjunctive ablation efficacy of saline-coupled bipolar radiofrequency systems in the surgical treatment of patients with benign or intermediate bone tumors. Secondary Objective: To assess the intraoperative safety of saline-coupled bipolar radiofrequency systems in patients with benign or intermediate bone tumors.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.在过去5年内已知来自非肌肉骨骼系统的恶性肿瘤的诊断;
2.合并转移性骨肿瘤或恶性转化;
3.术前接受过化疗、放疗/靶向治疗;
4.关键数据缺失(如手术记录不完整、失访);
5.就受试者和研究者所知,受试者可能无法完成所有研究方案要求的研究访视或程序,和/或无法遵守所有要求的研究程序(例如临床结局评估);
6.具有不稳定的全身性疾病,包括活动性感染、未控制的高血压、不稳定性心绞痛、充血性心力衰竭或心肌梗死;
7.经研究者判断认为不适合参与本研究的良性及中间型骨肿瘤患者;

Exclusion criteria:

1.History of non-musculoskeletal malignancy within the past 5 years;
2.Concurrent metastatic bone tumors or malignant transformation;
3.Prior chemotherapy, radiotherapy, or targeted therapy before surgery;
4.Critical data missing (e.g., incomplete surgical records, loss to follow-up);
5.Inability to comply with study requirements, including completion of follow-up visits or adherence to protocol-specified procedures (e.g., clinical outcome assessments), as judged by the investigator or subject;
6.Unstable systemic diseases, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction;
7.Other conditions deemed ineligible for participation by the investigator (e.g., atypical clinical presentation or high surgical risk);

研究实施时间:

Study execute time:

From 2025-05-31 00:00:00 To 2027-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-30 00:00:00 To 2025-12-08 00:00:00

干预措施:

Interventions:

组别:

盐水耦联双极射频系统组

样本量:

60

Group:

Saline-Coupled Bipolar Radiofrequency System Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组(传统电刀组)

样本量:

80

Group:

Control Group (Conventional Electrocautery Group)

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

南方医科大学第三附属医院(广东省骨科研究院) 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Hospital of Southern Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肿瘤原位复发或转移

指标类型:

主要指标

Outcome:

Local recurrence and/or metastasis

Type:

Primary indicator

测量时间点:

第 1、3、6、12、18、24个月(24个月后每年1次)

测量方法:

CT或者X线

Measure time point of outcome:

Follow-up at 1, 3, 6, 12, 18, and 24 months (annually thereafter)

Measure method:

CT or X-ray

指标中文名:

无复发生存期

指标类型:

主要指标

Outcome:

Recurrence-free survival

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

复发率

指标类型:

主要指标

Outcome:

Recurrence rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后各类型并发症发生率

指标类型:

次要指标

Outcome:

Incidence of Various Postoperative Complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

发生时间

指标类型:

次要指标

Outcome:

Occurrence Time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

文章发表后,邮件发送申请

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the article is published, send the application by email

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

据采集由病例记录表(CRF)记录,通过电子采集管理系统管理(EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is recorded via Case Report Forms (CRFs) and managed through an Electronic Data Capture (EDC) system.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-12-23 17:27:33